title: Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.
abstract: The best initial therapy for elderly patients with chronic lymphocytic leukemia (CLL) has not yet been defined. We investigated the activity of lenalidomide as initial therapy for elderly patients with CLL. Sixty patients with CLL 65 years of age and older received treatment with lenalidomide orally 5 mg daily for 56 days, then titrated up to 25 mg/d as tolerated. Treatment was continued until disease progression. At a median follow-up of 29 months, 53 patients (88%) are alive and 32 patients (53%) remain on therapy. Estimated 2-year progression-free survival is 60%. The overall response rate to lenalidomide therapy is 65%, including 10% complete response, 5% complete response with residual cytopenia, 7% nodular partial response, and 43% partial response. Neutropenia is the most common grade 3 or 4 treatment-related toxicity observed in 34% of treatment cycles. Major infections or neutropenic fever occurred in 13% of patients. Compared with baseline levels, we noted an increase in serum immunoglobulin levels across all classes, and a reduction in CCL3 and CCL4 plasma levels was noted in responding patients. Lenalidomide therapy was well tolerated and induced durable remissions in this population of elderly, symptomatic patients with CLL. This study was registered at www.clinicaltrials.gov as #NCT00535873.
authors: Departments of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
authors: Xavier C
authors: XC
authors: Badoux
authors: Michael J
authors: MJ
authors: Keating
authors: Sijin
authors: S
authors: Wen
authors: Bang-Ning
authors: BN
authors: Lee
authors: Mariela
authors: M
authors: Sivina
authors: James
authors: J
authors: Reuben
authors: William G
authors: WG
authors: Wierda
authors: Susan M
authors: SM
authors: O'Brien
authors: Stefan
authors: S
authors: Faderl
authors: Steven M
authors: SM
authors: Kornblau
authors: Jan A
authors: JA
authors: Burger
authors: Alessandra
authors: A
authors: Ferrajoli
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D016131:Lymphocyte Subsets / Q000166:cytology / Q000187:drug effects; D008297:Male; D020360:Neoadjuvant Therapy; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide